Zynex (ZYXI) Expected to Announce Earnings on Tuesday

Zynex (NASDAQ:ZYXI) is expected to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $53.65 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Zynex Stock Performance

Shares of ZYXI opened at $7.35 on Monday. The firm has a market cap of $234.07 million, a PE ratio of 49.00 and a beta of 0.81. The stock’s fifty day moving average price is $7.75 and its two-hundred day moving average price is $8.03. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. Zynex has a 1 year low of $7.00 and a 1 year high of $13.19.

Insider Activity at Zynex

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total transaction of $76,800.00. Following the sale, the chief financial officer now directly owns 19,738 shares in the company, valued at approximately $151,587.84. The trade was a 33.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 30,000 shares of company stock worth $227,100. 52.13% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Zynex in a research note on Friday, December 6th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.